Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD
Journal of the American Society of Nephrology · 2025-05 · 36 (5) · 890-900
DOI: 10.1681/asn.0000000540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 01.11.2024. Verfasst von Vikas S Sridhar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Key Points Poor glycemic control in type 1 diabetes and CKD is associated with a higher risk of CKD progression. In a subgroup of inTandem participants with type 1 diabetes and CKD, adding sotagliflozin to insulin reduced HbA1c, body weight, and systolic BP without increasing severe hypoglycemia, compared with adding placebo. In participants with type 1 diabetes and CKD, sotagliflozin did not significantly increase the risk of DKA, however, there were a small number of diabetic ketoacidosis events.
Background
This analysis evaluated the efficacy and safety of sotagliflozin, a dual sodium-glucose cotransporter 1 and 2 inhibitor, added to insulin in patients with type 1 diabetes and CKD.
Methods
We used data from the 52-week pooled inTandem 1 and 2 trials and the 24-week inTandem 3 trial to assess the effects of sotagliflozin (200 mg [inTandem 1 and 2 only] or 400 mg daily) versus placebo on glycated hemoglobin (HbA1c; primary end point), body weight, systolic BP, insulin dose, and safety end points including adjudicated severe hypoglycemia and diabetic ketoacidosis (DKA), stratified by CKD.
Results
CKD was identified in 237/1575 inTandem 1 and 2 participants and 228/1402 inTandem 3 participants. At week 24, significant, placebo-adjusted reductions in HbA1c were observed—inTandem 1 and 2: non-CKD subgroup (sotagliflozin 200 mg: −0.4%, 95% confidence interval [CI], −0.4 to −0.3; 400 mg: −0.4%, 95% CI, −0.5 to −0.3) and CKD subgroup (sotagliflozin 200 mg: −0.4%, 95% CI, −0.6 to −0.1; 400 mg: −0.3%, 95% CI, −0.5 to −0.1). For systolic BP, there was a significant reduction at week 24 with sotagliflozin in the non-CKD subgroup, but no effect in the CKD subgroup in inTandem 1 and 2. At week 52, the incidence of severe hypoglycemia was lower with sotagliflozin (7% on 200 mg and 4% on 400 mg) compared with placebo (17%) in the CKD subgroup of inTandem 1 and 2, whereas the incidence of severe hypoglycemia was 5%–6% across non-CKD subgroups. The incidence of adjudicated DKA at week 52 was 1%, 5%, and 3% for placebo, 200, and 400 mg in the CKD subgroup compared with 0%, 3%, and 4% in the non-CKD subgroup, respectively. The results were generally similar in inTandem 3, except systolic BP was significantly reduced with sotagliflozin versus placebo in CKD and non-CKD subgroups.
Conclusions
In participants with type 1 diabetes and CKD, sotagliflozin treatment had similar HbA1c, body weight, and systolic BP lowering effects as in participants with type 1 diabetes without CKD. In addition, sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of DKA among a small number of DKA events. Clinical Trial registration numbers: NCT02384941, NCT02421510, NCT02531035.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
- Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.
- Department of Diabetes, Endocrinology, and Clinical Research, Children's and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany.
- Research Division, Department of Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Vikas S Sridhar, Ayodele Odutayo, Satish Garg, Thomas Danne, Alessandro Doria, Michael Mauer, Michael J Davies
Förderung
- NIDDK NIH HHS
Zitieren
APA
Sridhar, V. S., Odutayo, A., Garg, S., Danne, T., Doria, A., Mauer, M., Davies, M. J., Banks, P., Girard, M., & Cherney, D. Z. I. (2025). Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. Journal of the American Society of Nephrology, 36(5), 890-900. https://doi.org/10.1681/asn.0000000540
Vancouver
Sridhar VS, Odutayo A, Garg S, Danne T, Doria A, Mauer M, et al. Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. Journal of the American Society of Nephrology. 2025;36(5):890-900. doi:10.1681/asn.0000000540
BibTeX
@article{Sridhar2025,
author = {Sridhar, Vikas S and Odutayo, Ayodele and Garg, Satish and Danne, Thomas and Doria, Alessandro and Mauer, Michael and Davies, Michael J and Banks, Phillip and Girard, Manon and Cherney, David Z I},
title = {Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD},
journal = {Journal of the American Society of Nephrology},
year = {2025},
volume = {36},
number = {5},
pages = {890--900},
doi = {10.1681/asn.0000000540}
}
EUVIMED